Breast Cancer

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses ongoing research in triple-negative breast cancer (TNBC).

Women between the ages of 30 and 39 who have at least 1 of 3 risk factors may benefit from starting their annual mammography screening at age 30.

Ruth O’Regan, MD, discusses the current landscape of hormone receptor–positive breast cancer and the unanswered questions that still need to be addressed.

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical management of patients with node-positive breast cancer.

The treatment options for women with hormone receptor (HR)–positive metastatic breast cancer have evolved rapidly in the past decade, with the introduction of the CDK4 and CDK6 inhibitors representing a major advance.

Fabrice Andre, MD, PhD, discusses the SOLAR-1 findings and their impact on the breast cancer landscape.

Adam M. Brufsky, MD, PhD, highlights novel treatment approaches being explored in the triple-negative breast cancer space.

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the implementation of precision medicine in breast cancer.

Kathleen Toomey, MD, who specializes in hematology and medical oncology and practices at the Steeplechase Cancer Center, discusses the results of the TAILORx trial, which reported that some patients with early-stage breast cancer can avoid chemotherapy.

Dennis Fitzgerald, MD, a specialist in breast cancer, lung cancer, non-Hodgkin lymphoma and hemochromatosis, Hackensack Meridian Health Riverview Medical Center, discusses the pivotal TAILORx trial.

The European Medicine’s Agency Committee for Medicinal Products for Human Use has recommended expanding the approval of ribociclib (Kisqali) in women with HR+/HER2-negative breast cancer to include use in combination with fulvestrant (Faslodex).

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses resistance to CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Terry L. Evans, MD, clinical assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the tolerability of CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.